Untitled

Abstract

The treatment of urinary incontinence represents an important medico-social problem, notwithstanding the offered 90 products of treatment. The authors summarice their experience on the treatment of urinary incontinence with clenbuterol for the period 1988-1997. During this period total of 335 patients (163 women and 72 men), aged between 30 and 73 were treated. The medicine was used in the treatment of women with stress incontinence (60) and urge incontinence (103). In cases of combination between urinary incontinence and hyperreflexy of the detrusor, and antiholynergic therapy was used. It was used after surgery of the adenoma of the prostate in men, aged 62-73: in 50 of them after transvesical prostatectomy, and in 22 after transurethral resection of the prostate. The authors determine the period of using the product in the different kinds of incontinence. Clenbuterol can be effective only when sfincter activity is preserved, which is proved by means of urodynamic tests. The durability of treatment was stable in 86% of treated women, and in 76.3% of treated men. The authors determine the indications and contraindications of administration of celbuterol. They analise the changes in the hydrodynamic of the lower urinary tract in the patients with urinary incontinence after clenbuterol therapy.

Therapeutic potential of muscle growth promoters in a stress urinary incontinence model

“…Moreover, ␤ 2 -adrenergic receptor agonists also relax the detrusor muscle during bladder filling (57,59). In a randomized controlled trial, clenbuterol induced significant clinical improvement and normalized the main urodynamic indicators of SUI in both men and women in the presence of normal sphincter activity (65). In addition, a limited open-label trial reported a similar rate of improvement in men with mild to moderate SUI after prostatectomy (41).…”

“…Although a few studies have shown that clenbuterol could relieve symptoms of stress and urge incontinence (41, 65), we did not observe a therapeutic potential of clenbuterol in either urethral function or morphology. Previous clinical trials administered clenbuterol with a dose at 10 -20 g two or three times daily for 2-4 wk to enrolled subjects (22,28,30,58,62,65). The dose used in this experiment was higher than the clinical dose and may suggest that rats are less sensitive to this ␤ 2 -adrenoceptor agonist.…”

“…Therefore, we might have seen a greater effect with an increased dose. In addition, results from those trials showed that clenbuterol is effective only in subjects with mild to moderate incontinence and normal sphincter activity (41,65), suggesting that clenbuterol may not improve urinary continence in the DI PNC ϩ VD SUI model that we used, which induces severe urethral sphincter injury (44).…”

Lower Urinary Tract Symptoms in Myasthenia Gravis

“…Therefore, to treat overactive bladder in MG, serotonergic drugs (e.g., serotonin-noradrenaline reuptake inhibitors) [ 13 ] and selective adrenergic beta 3 receptor agonists [ 20 ] may be the best options. When stress urinary incontinence is proved by examination and tests, clenbuterol (an adrenergic beta 2 receptor agonist) [ 21 ] and mesh surgeries for counteracting pelvic floor descent are good choices. Again, urodynamics has a place, but clinical examination is still important to perform in all MG patients.…”